OncoSec Medical (ONCS) Cut to Neutral at HC Wainwright

OncoSec Medical (NASDAQ:ONCS) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, Marketbeat.com reports.

A number of other research firms also recently weighed in on ONCS. Dawson James reissued a “buy” rating on shares of OncoSec Medical in a report on Monday, July 16th. Piper Jaffray Companies increased their target price on OncoSec Medical to $5.00 and gave the company an “overweight” rating in a report on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $4.00.

ONCS stock opened at $0.84 on Wednesday. OncoSec Medical has a fifty-two week low of $0.68 and a fifty-two week high of $2.95. The stock has a market capitalization of $51.72 million, a price-to-earnings ratio of -0.79 and a beta of 2.28.

A number of hedge funds have recently bought and sold shares of the business. DRW Securities LLC lifted its holdings in OncoSec Medical by 157.1% in the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 110,000 shares during the period. Millennium Management LLC increased its position in OncoSec Medical by 19.5% in the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after buying an additional 194,739 shares in the last quarter. BlackRock Inc. increased its position in OncoSec Medical by 1,303.5% in the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after buying an additional 221,916 shares in the last quarter. 683 Capital Management LLC purchased a new stake in OncoSec Medical in the second quarter worth about $414,000. Finally, Nexthera Capital LP increased its position in OncoSec Medical by 26.6% in the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after buying an additional 550,000 shares in the last quarter. 23.13% of the stock is currently owned by institutional investors.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

See Also: What are the Benefits of Index Funds?

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply